News

With just one slide and three minutes, fourth-year graduate student Erin Keblish described how she is developing a carbon nanotube-based sensor that could act like a “smoke detector” for early signs of deadly sepsis, during Weill Cornell Medicine’s ninth annual Three-Minute Thesis (3MT®) competition on November 13.

The center connects health policy researchers across Cornell’s campuses to help shape effective health policy at the federal, state and local levels.

The awards recognized Dr. Harrington's career and leadership achievements.

Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor for the first time, uncovering how it functions, which may enable better drug targeting of the receptor for diseases like hypertension and heart failure.

Weill Cornell Medicine has been awarded the Health Professions Higher Education Excellence in Diversity (HEED) Award by INSIGHT Into Diversity magazine, for the seventh consecutive year. 

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

The award seeks to increase the number of early-stage investigators and enhance the diversity of the cancer research workforce to accelerate the fight against cancer.

Weill Cornell Medicine researchers have received a $6.2 million, five-year grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution Positron Emission Tomography (PET) scanner that can detect the earliest stages of Alzheimer’s disease.

Dr. Chani Traube, the Gerald M. Loughlin, MD Professor of Pediatrics at Weill Cornell Medicine, has been awarded a $3.4 million grant, with the possibility of extending to a total of $17 million over five years, from the National Institutes of Health, for a large-scale clinical trial called Optimizing Pain Treatment in Children on Mechanical ventilation (OPTICOM).

 Awards, honors and achievements for the month of October.

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition

An MRI-guided treatment for essential tremor is safe and effective in patients who already underwent the procedure for their dominant hand, a new study shows. 

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. 

Investigators from Weill Cornell Medicine have discovered a defense mechanism that protects skin cancer cells from oxidative stress and helps them spread.

A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.

Dr. Robert M. Califf, U.S. Food and Drug Administration commissioner, and Dr. Robert A. Harrington, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, sat down for a fireside chat Oct. 15 in Weill Cornell Medicine's Uris Auditorium. 

Dr. Silvia Formenti, chair of the Department of Radiation Oncology, and Dr. Massimo Loda, chair of the Department of Pathology and Laboratory Medicine, have been elected to the National Academy of Medicine.

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine.

How can medicine and public health address unregulated and potentially harmful marijuana products?